| Autor: |
Angel T. Alvarado, Juan Cotuá, Maryori Delgado, Alexis Morales, Ana María Muñoz, César Li Amenero, María R. Bendezú, Jorge A. García, Doris Laos-Anchante, Felipe Surco-Laos, Berta Loja, Mario Bolarte-Arteaga, Mario Pineda-Pérez |
| Jazyk: |
English<br />Spanish; Castilian |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Journal of Pharmacy & Pharmacognosy Research, Vol 10, Iss 6, Pp 1117-1125 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
0719-4250 |
| DOI: |
10.56499/jppres22.1500_10.6.1117 |
| Popis: |
Context: Therapeutic drug monitoring (TDM) allows personalizing the dose of valproic acid in patients with epilepsy to optimize drug therapy, minimize adverse effects and detect interactions. Aims: To determine valproic acid concentrations in serum samples from people with epilepsy and to analyze its clinical implications. Methods: Cloned donor enzyme immunoassay; descriptive, cross-sectional, non-randomized, convenience recruitment study of 57 voluntary patients with epilepsy (n = 39 male, 68.42%; n = 18 female, 31.58%) aged between 19 and 62 years. After three months of treatment with valproic acid, a single blood sample was collected from each volunteer at a minimal concentration. Results: Serum drug concentrations 51.30-100.10 mg/L (SD 5.94) and level/dose 2.17-5.31 (SD 1.14) were observed. Association was shown between the dose ratio/dose of valproic acid (R2 = 0.8693; p α = 0.05). Conclusions: Serum valproic acid concentrations are within the therapeutic range, and there is a significant inverse linear correlation between dose ratio/dose, which must be considered to personalize the dose and optimize the pharmacotherapeutic result. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
